GeoVax Labs, Inc. and ProBioGen announced the signing of a landmark commercial license agreement for ProBioGen's groundbreaking AGE1.CR.pIX suspension cell line. The agreement will empower GeoVax to enhance the manufacturing capabilities of its entire Modified Vaccinia Ankara (MVA) based vaccine portfolio. ProBioGen's AGE1.CR.pIX suspension cell line is an innovative and proven platform that enables high-yield and scalable production, ensuring efficient industrial manufacturing processes.

This translates to cost-effectiveness and increased productivity for vaccine developers. The AGE1.CR.pIX cell line's versatility allows it to support a wide range of viruses and vaccine types, enhancing its suitability for various vaccines in development and as a replacement for traditional production systems. Additionally, AGE1.CR.pIX's robust growth and genetic stability ensure consistent and reliable production, leading to the delivery of safe and effective vaccines. MVA grows particularly well on this cell line, making it even more advantageous for vaccine development.

By leveraging this modern production technology, GeoVax aims to accelerate the manufacturing of its entire vaccine pipeline. This multi-product license represents a strong commitment to improving global access to life-saving vaccines.